Skip to main content

Loading market data...

GILD

Gilead Sciences, Inc.

NASDAQ • United states

$156.51

+$3.44

(+2.25%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Gilead Sciences, Inc. (GILD)

Unavailable

Quotes may be delayed

$194.07B

Market Cap

5,790,677

Volume

Unavailable

P/E Ratio

2.10%

Div Yield

Gilead Sciences, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 333 LAKESIDE DR, FOSTER CITY, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

8 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Gilead Sciences, Inc..

7 Aug 2026

Gilead Sciences, Inc. filed Form 10-Q

Gilead Sciences, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

5 Aug 2026

Gilead Sciences, Inc. reported Operating or financial results

Gilead Sciences, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

28 May 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Gilead Sciences, Inc..

21 May 2026

Gilead Sciences, Inc. reported A material agreement

Gilead Sciences, Inc. filed an 8-K covering a material agreement, a material financing obligation, another company event, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$5.41B

Total assets (USD)$49.36B

Shareholders' equity (USD)$11.83B

Long-term debt (USD)$23.83B

Debt due within a year (USD)$2.41B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$7.80B	−$10.39B	−$10.50B	−$8.45	10-Q · 6 Aug 2026
Q1 2026	$6.96B	$2.59B	$2.02B	$1.61	10-Q · 7 May 2026
Q4 2025	$7.93B	$1.98B	$2.18B	Unavailable	10-K · 24 Feb 2026
Q3 2025	$7.77B	$3.33B	$3.05B	$2.43	10-Q · 7 Nov 2025
Q2 2025	$7.08B	$2.47B	$1.96B	$1.56	10-Q · 7 Aug 2025
Q1 2025	$6.67B	$2.24B	$1.32B	$1.04	10-Q · 7 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $160.00

2.2% upside potential

📈

Strong Buy

Unavailable

👍

Buy

17

⏸️

Hold

4

📉

Sell

0

21 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 10:47 UTC Targets range 126.00–177.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

15

Oct 2026

Dickinson Andrew D

Chief Financial Officer

Open-market sale

$156.22 per share

3,000 shares

15

Oct 2026

Mercier Johanna

Chief Comm & Corp Aff Officer

Open-market sale

$156.22 per share

3,000 shares

1

Oct 2026

O'Day Daniel Patrick

Director, Chairman & CEO

Open-market sale

$147.90 per share

15,000 shares

22

Sep 2026

Burkhart Erin

SVP, Controllership

Option exercise

Unavailable per share

2,223 shares

22

Sep 2026

Burkhart Erin

SVP, Controllership

Tax withholding

$152.67 per share

768 shares

15

Sep 2026

Dickinson Andrew D

Chief Financial Officer

Open-market sale

$145.29 per share

3,000 shares

15

Sep 2026

Mercier Johanna

Chief Comm & Corp Aff Officer

Open-market sale

$144.22 per share

3,000 shares

10

Sep 2026

Dickinson Andrew D

Chief Financial Officer

Option exercise

Unavailable per share

2,797 shares

10

Sep 2026

Dickinson Andrew D

Chief Financial Officer

Tax withholding

$144.81 per share

1,347 shares

10

Sep 2026

Berger Dietmar

Chief Medical Officer

Option exercise

Unavailable per share

533 shares

Top Shareholders

Vanguard Group Inc

125,178,855 shares

1.862% change

12/31/2025

Blackrock, Inc.

121,844,108 shares

-0.904% change

6/30/2026

Vanguard Capital Management Llc

81,091,734 shares

-2.393% change

6/30/2026

Fmr Llc

66,870,816 shares

-7.157% change

6/30/2026

State Street Corp

61,216,552 shares

-0.517% change

6/30/2026

Capital World Investors

40,988,975 shares

-0.714% change

6/30/2026

Invesco Ltd.

39,819,151 shares

-4.346% change

6/30/2026

Vanguard Portfolio Management Llc

35,316,168 shares

-5.96% change

6/30/2026

Geode Capital Management, Llc

30,065,642 shares

-2.241% change

6/30/2026

Price T Rowe Associates Inc /Md/

29,996,694 shares

14.082% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 10:47 UTC· 19 hours ago

Research coverage and investment tools

Gilead Sciences, Inc. (GILD) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$156.51 on 20 Oct 2026. That is 91% of the way from its 52-week low of US$114.02 to its 52-week high of US$160.51. It paid US$3.25 a share in dividends over the last 12 months, a dividend yield of 2.10%. The latest ex-dividend date on file is 15 Sep 2026. Its market capitalisation was US$194.07 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$7.80B	−$10.39B	−$10.50B	−$8.45	—	-133.2%	$3.43B	10-Q · 6 Aug 2026 (opens in a new tab)
Q1 2026	$6.96B	$2.59B	$2.02B	$1.61	—	37.2%	$2.43B	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$7.93B	$1.98B	$2.18B	Unavailable	—	25.0%	$3.12B	10-K · 24 Feb 2026 (opens in a new tab)
Q3 2025	$7.77B	$3.33B	$3.05B	$2.43	—	42.8%	$3.96B	10-Q · 7 Nov 2025 (opens in a new tab)
Q2 2025	$7.08B	$2.47B	$1.96B	$1.56	—	34.9%	$720.00M	10-Q · 7 Aug 2025 (opens in a new tab)
Q1 2025	$6.67B	$2.24B	$1.32B	$1.04	—	33.6%	$1.65B	10-Q · 7 May 2025 (opens in a new tab)

Cash and equivalents: $5.41B
Total assets: $49.36B
Shareholders' equity: $11.83B
Long-term debt: $23.83B
Debt due within a year: $2.41B

SCHEDULE 13D/A · 8 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Gilead Sciences, Inc..
10-Q · 7 Aug 2026

Gilead Sciences, Inc. filed Form 10-Q (opens in a new tab)

Gilead Sciences, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 5 Aug 2026

Gilead Sciences, Inc. reported Operating or financial results (opens in a new tab)

Gilead Sciences, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
SCHEDULE 13D/A · 28 May 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Gilead Sciences, Inc..
8-K · 21 May 2026 · Material agreement Signed

Gilead Sciences, Inc. reported A material agreement (opens in a new tab)

Gilead Sciences, Inc. filed an 8-K covering a material agreement, a material financing obligation, another company event, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Dickinson Andrew D Chief Financial Officer	15 Oct 2026	Open-market sale (S)	−3,000	$156.22	Form 4 (opens in a new tab)
Mercier Johanna Chief Comm & Corp Aff Officer	15 Oct 2026	Open-market sale (S)	−3,000	$156.22	Form 4 (opens in a new tab)
O'Day Daniel Patrick Director, Chairman & CEO	1 Oct 2026	Open-market sale (S)	−15,000	$147.90	Form 4 (opens in a new tab)
Burkhart Erin SVP, Controllership	22 Sep 2026	Option exercise (M)	+2,223	—	Form 4 (opens in a new tab)
Burkhart Erin SVP, Controllership	22 Sep 2026	Tax withholding (F)	−768	$152.67	Form 4 (opens in a new tab)
Dickinson Andrew D Chief Financial Officer	15 Sep 2026	Open-market sale (S)	−3,000	$145.29	Form 4 (opens in a new tab)
Mercier Johanna Chief Comm & Corp Aff Officer	15 Sep 2026	Open-market sale (S)	−3,000	$144.22	Form 4 (opens in a new tab)
Dickinson Andrew D Chief Financial Officer	10 Sep 2026	Option exercise (M)	+2,797	—	Form 4 (opens in a new tab)
Dickinson Andrew D Chief Financial Officer	10 Sep 2026	Tax withholding (F)	−1,347	$144.81	Form 4 (opens in a new tab)
Berger Dietmar Chief Medical Officer	10 Sep 2026	Option exercise (M)	+533	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	125,178,855	1.862%
Blackrock, Inc.	6/30/2026	121,844,108	-0.904%
Vanguard Capital Management Llc	6/30/2026	81,091,734	-2.393%
Fmr Llc	6/30/2026	66,870,816	-7.157%
State Street Corp	6/30/2026	61,216,552	-0.517%
Capital World Investors	6/30/2026	40,988,975	-0.714%
Invesco Ltd.	6/30/2026	39,819,151	-4.346%
Vanguard Portfolio Management Llc	6/30/2026	35,316,168	-5.96%
Geode Capital Management, Llc	6/30/2026	30,065,642	-2.241%
Price T Rowe Associates Inc /Md/	6/30/2026	29,996,694	14.082%

Previous close: 153.07 USD
Day range: 154.02 – 157.48 USD
52-week range: 114.02 – 160.51 USD
Volume: 5,790,677
Market cap: $194.07B
Average volume: 5,618,666
EPS (FY 2025, diluted): 6.78 USD
Dividends (last 12 months): 3.25 USD
Dividend yield: 2.10%
Ex-dividend date: 15 Sep 2026
Shares outstanding: 1.24B
Beta (5Y monthly): 0.38

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:13 UTC· 20 minutes ago

Dividends: Yahoo Finance dividend history (opens in a new tab) Observed 22 Oct 2026, 06:13 UTC· 20 minutes ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding. What dividend yield leaves out: dividend yield vs total return

This research is not available for GILD yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.